Aligos Therapeutics, Inc. (ALGS)

Market Cap	50.01M
Revenue (ttm)	3.17M
Net Income (ttm)	-74.18M
Shares Out	6.15M
EPS (ttm)	-9.47
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	114,374
Open	7.73
Previous Close	8.04
Day's Range	7.09 - 8.24
52-Week Range	3.76 - 46.80
Beta	2.78
Analysts	Strong Buy
Price Target	70.00 (+761.01%)
Earnings Date	Aug 6, 2025

About SIX

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I cli...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 16, 2020
• Employees: 70
• Stock Exchange: NASDAQ
• Ticker Symbol: ALGS
• Website: https://www.aligos.com

Financial Performance

In 2024, Aligos Therapeutics's revenue was $3.95 million, a decrease of -74.60% compared to the previous year's $15.53 million. Losses were -$131.21 million, 49.6% more than in 2023.

Analyst Summary

According to one analyst, the rating for ALGS stock is "Strong Buy" and the 12-month stock price target is $70.0.

Price Target

$70.0

(761.01% upside)

Analyst Consensus: Strong Buy